457 related articles for article (PubMed ID: 30416079)
1. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
[TBL] [Abstract][Full Text] [Related]
2. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
3. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
5. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
6. [Expression of B cell transposition gene 3 in pancreatic ductal adenocarcinoma and its prognostic value].
Chen J; Zhou ZC; Liu WB; Wang J; Chen XJ; Shen YY; Zhong ZX
Zhonghua Wai Ke Za Zhi; 2017 Nov; 55(11):863-867. PubMed ID: 29136736
[No Abstract] [Full Text] [Related]
7. BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance.
Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):437-444. PubMed ID: 27802195
[TBL] [Abstract][Full Text] [Related]
8. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
9. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
10. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
11. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
[No Abstract] [Full Text] [Related]
13. Aberrant expression of Arpin in human breast cancer and its clinical significance.
Liu X; Zhao B; Wang H; Wang Y; Niu M; Sun M; Zhao Y; Yao R; Qu Z
J Cell Mol Med; 2016 Mar; 20(3):450-8. PubMed ID: 26648569
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic significance of aberrant Arpin expression in gastric cancer.
Li T; Zheng HM; Deng NM; Jiang YJ; Wang J; Zhang DL
World J Gastroenterol; 2017 Feb; 23(8):1450-1457. PubMed ID: 28293092
[TBL] [Abstract][Full Text] [Related]
16. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
17. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Zhang SR; Yao L; Wang WQ; Xu JZ; Xu HX; Jin W; Gao HL; Wu CT; Qi ZH; Li H; Li S; Ni QX; Yu XJ; Fu DL; Liu L
Ann Surg Oncol; 2018 Dec; 25(13):3984-3993. PubMed ID: 30171511
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
20. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
